Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 126

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 126
---
 regulatory approval for APHEXDA (motixafortide) in September 2023. In October 2023, we out-licensed the rights to motixafortide
for all indications in substantially all of Asia, and in November 2024, we out-licensed the global rights (other than in Asia) to motixafortide
for all indications, other than solid tumors. As a result of the November 2024 transaction, we shut down our independent commercialization
activities in the United States and refocused our operations on development activities in Israel in the fields of oncology (including
solid tumors) and rare diseases, at a significantly reduced annual cash burn rate. Our ability to generate revenues from commercialization
and achieve profitability will be subject to Gloria License Agreement and the Ayrmid License Agreement and depend on our commercialization
partners’ ability to successfully commercialize products, including any of our current product and product candidates, and other
product candidates that we may develop, in-license or acquire in the future. As such, it is not possible for us to predict with any
degree of accuracy any known trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect
on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported
financial information to not necessarily be indicative of future operating results or financial conditions. However, to the extent possible,
certain trends, uncertainties, demands, commitments and events are in this “ Operating and Financial Review and Prospects.”

E. Critical Accounting Estimates

Our consolidated financial statements are prepared in conformity
with IFRS, as issued by the IASB. In preparing our consolidated financial statements, we make judgements, estimates and assumptions about
the application of our accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Our critical
accounting judgements and sources of estimation uncertainty are described in Note 4 to our consolidated financial statements, which are
included elsewhere in this Annual Report on Form 20-F.

70

ITEM 6. DIRECTORS, SENIOR
MANAGEMENT AND EMPLOYEES

A. Executive Officers and Directors

The following table sets forth information for our executive officers
and directors as of March 16, 2025. Unless otherwise stated, the address for our directors and officers is c/o BioLineRx Ltd., 2 HaMa’ayan
Street, Modi’in 7177871, Israel.

  Name